Karpenko Larisa I, Rudometov Andrey P, Sharabrin Sergei V, Shcherbakov Dmitry N, Borgoyakova Mariya B, Bazhan Sergei I, Volosnikova Ekaterina A, Rudometova Nadezhda B, Orlova Lyubov A, Pyshnaya Inna A, Zaitsev Boris N, Volkova Natalya V, Azaev Mamedyar Sh, Zaykovskaya Anna V, Pyankov Oleg V, Ilyichev Alexander A
State Research Center of Virology and Biotechnology "Vector", Koltsovo, 630559 Novosibirsk, Russia.
Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Vaccines (Basel). 2021 Jan 21;9(2):76. doi: 10.3390/vaccines9020076.
One of the key stages in the development of mRNA vaccines is their delivery. Along with liposome, other materials are being developed for mRNA delivery that can ensure both the safety and effectiveness of the vaccine, and also facilitate its storage and transportation. In this study, we investigated the polyglucin:spermidine conjugate as a carrier of an mRNA-RBD vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. The conditions for the self-assembling of mRNA-PGS complexes were optimized, including the selection of the mRNA:PGS charge ratios. Using dynamic and electrophoretic light scattering it was shown that the most monodisperse suspension of nanoparticles was formed at the mRNA:PGS charge ratio equal to 1:5. The average hydrodynamic particles diameter was determined, and it was confirmed by electron microscopy. The evaluation of the zeta potential of the investigated complexes showed that the particles surface charge was close to the zero point. This may indicate that the positively charged PGS conjugate has completely packed the negatively charged mRNA molecules. It has been shown that the packaging of mRNA-RBD into the PGS envelope leads to increased production of specific antibodies with virus-neutralizing activity in immunized BALB/c mice. Our results showed that the proposed polycationic polyglucin:spermidine conjugate can be considered a promising and safe means to the delivery of mRNA vaccines, in particular mRNA vaccines against SARS-CoV-2.
mRNA疫苗开发的关键阶段之一是其递送。除了脂质体,还在开发其他用于mRNA递送的材料,这些材料既能确保疫苗的安全性和有效性,又便于其储存和运输。在本研究中,我们研究了聚葡萄糖:亚精胺缀合物作为编码SARS-CoV-2刺突蛋白受体结合域(RBD)的mRNA-RBD疫苗的载体。优化了mRNA-PGS复合物的自组装条件,包括mRNA:PGS电荷比的选择。使用动态和电泳光散射表明,在mRNA:PGS电荷比等于1:5时形成了最单分散的纳米颗粒悬浮液。测定了平均流体动力学颗粒直径,并通过电子显微镜进行了确认。对所研究复合物的zeta电位评估表明,颗粒表面电荷接近零点。这可能表明带正电荷的PGS缀合物已完全包裹了带负电荷的mRNA分子。结果表明,将mRNA-RBD包装到PGS包膜中可导致免疫的BALB/c小鼠中产生具有病毒中和活性的特异性抗体增加。我们的结果表明,所提出的聚阳离子聚葡萄糖:亚精胺缀合物可被认为是递送mRNA疫苗,特别是抗SARS-CoV-2的mRNA疫苗的一种有前景且安全的手段。